Merck

Levodopa inhibits the development of lens-induced myopia in chicks.

Scientific reports (2020-08-09)
Kate Thomson, Ian Morgan, Cindy Karouta, Regan Ashby
ABSTRACT

Animal models have demonstrated a link between dysregulation of the retinal dopamine system and the development of myopia (short-sightedness). We have previously demonstrated that topical application of levodopa in chicks can inhibit the development of form-deprivation myopia (FDM) in a dose-dependent manner. Here, we examine whether this same protection is observed in lens-induced myopia (LIM), and whether levodopa's protection against FDM and LIM occurs through a dopamine D1- or D2-like receptor mechanism. To do this, levodopa was first administered daily as an intravitreal injection or topical eye drop, at one of four ascending doses, to chicks developing LIM. Levodopa's mechanism of action was then examined by co-administration of levodopa injections with D1-like (SCH-23390) or D2-like (spiperone) dopamine antagonists in chicks developing FDM or LIM. For both experiments, levodopa's effectiveness was examined by measuring axial length and refraction after 4 days of treatment. Levodopa inhibited the development of LIM in a dose-dependent manner similar to its inhibition of FDM when administered via intravitreal injections or topical eye drops. In both FDM and LIM, levodopa injections remained protective against myopia when co-administered with SCH-23390, but not spiperone, indicating that levodopa elicits its protection through a dopamine D2-like receptor mechanism in both paradigms.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Spiperone, solid
Sigma-Aldrich
R(+)-SCH-23390 hydrochloride, ≥98% (HPLC), solid
Sigma-Aldrich
3,4-Dihydroxy-L-phenylalanine, ≥98% (TLC)